"A Common Anti-Inflammatory Therapy May Help Reduce Risk Of Developing Parkinson’s Disease"
A recent study from researchers at the Icahn School of Medicine at Mount Sinai provides new insights into a link between inflammatory bowel disease (IBD) and Parkinson's disease, and may have significant implications for the treatment and prevention of Parkinson's disease. The recent study, published in JAMA Neurology, shows that individuals with IBD are at a 28 percent higher risk of developing Parkinson's disease than those without IBD. "Systemic inflammation is a major component of IBD, and it's also thought to contribute to the neuronal inflammation found in Parkinson's disease," explained Inga Peter, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and lead investigator in the study. "We wanted to determine if anti-TNFα therapy, could mitigate a patient's risk in developing Parkinson's disease." The Mount Sinai team found a 78 percent reduction in the incidence of Parkinson's disease among IBD patients who were treated with anti-TNFα therapy when compared to those who were not.
- Inga Peter, PhD, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai
Additional coverage:
MedPage Today
Healio: Gastroenterology
Physician’s Briefing
Doctors Lounge
Medscape
Daily Mail
Politico New York
European Pharmaceutical Review
WSIL News
KLTV News
WDAM News
WALB News